Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Ofev® (nintedanib) – Expanded indication
March 9, 2020 - The FDA announced the approval of Boehringer Ingelheim’s Ofev (nintedanib), for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
